HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation

Recruiting N/A Interventional Study
Hepatocellular Carcinoma HCC
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
20 – 85
Sex
Any
Study type
Interventional
Purpose
Screening
Participants needed
476 (estimated)
Sponsor
Concord Repatriation General Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim of surveillance is to detect HCC at an early stage when it is still potentially curable. Currently only 4 out of 10 HCCs are detected at the early stage. Ultrasound surveillance for HCC has a wide ranging sensiti…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria * Patients with cirrhosis (all causes of cirrhosis, except obscure causes such as vascular or congenital fibrosis) AND reduced visualisation of their liver on ultrasound (vB and vC). * The criteria of cirrhosis can be obtained with any of the following methods: 1. Histological…
Contacts

Jessica Yang, MBBS

+61297676495

jessica.yang1@health.nsw.gov.au

CONTACT

Isaac Lui, MD

dr.isaac.lui@gmail.com

CONTACT